Loading…
NeuroSense Therapeutics Ltd. is projected to rise to $0.4726 by 2027, a +1% move from its current price of $0.467. NRSN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.4486 | $0.4674 | $0.487 | +0.09% |
| Aug 6 | $0.4414 | $0.4678 | $0.4958 | +0.18% |
| Aug 7 | $0.4361 | $0.4682 | $0.5027 | +0.26% |
| Aug 8 | $0.4317 | $0.4686 | $0.5088 | +0.35% |
| Aug 9 | $0.4279 | $0.4691 | $0.5142 | +0.44% |
| Aug 10 | $0.4245 | $0.4695 | $0.5191 | +0.53% |
| Aug 11 | $0.4215 | $0.4699 | $0.5238 | +0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4215 | $0.4699 | $0.5238 | +0.62% |
| Week 2 | $0.4054 | $0.4728 | $0.5513 | +1.24% |
| Week 3 | $0.3941 | $0.4757 | $0.5742 | +1.86% |
| Week 4 | $0.3852 | $0.4786 | $0.5948 | +2.49% |
| Week 5 | $0.3777 | $0.4816 | $0.614 | +3.12% |
| Week 6 | $0.3713 | $0.4845 | $0.6323 | +3.76% |
| Week 7 | $0.3657 | $0.4875 | $0.6499 | +4.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. (NRSN) is currently priced at $0.4802 with a market cap of $17.34M and a rank of 4915.
The forecast landscape shows a path of gradual price movement from the current level toward higher levels over the coming years, with 2026 averaging $0.4802 and rising to $0.7543 by 2030, and longer-term targets in the $1.03 to $2.62 range by 2040–2050. The three high-water marks in the forecast occur in 2029 ($1.11 max), 2030 ($1.23 max), and 2050 ($5.91 max).
Forecasts indicate a bullish tilt beginning in 2029 and extending through 2050, with the highest estimated upside seen in 2050 (avg $2.62; max $5.91; ROI 446.6; sentiment BULLISH). Shorter-horizon figures remain modest or flat around the current price in 2026–2028, reflecting a near-term neutral stance.
A major floor 49.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.4% away) — a key level to hold.
The nearest ceiling, 72.4% above — a clean break opens room to run.
A major ceiling 103.4% above — clearing it would confirm fresh momentum.
Key NRSN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRSN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5132 | Sell | $0.5112 | Sell |
| MA 10 | $0.5863 | Sell | $0.5641 | Sell |
| MA 20 | $0.6495 | Sell | $0.6225 | Sell |
| MA 50 | $0.7214 | Sell | $0.6959 | Sell |
| MA 100 | $0.7538 | Sell | $0.7614 | Sell |
| MA 200 | $0.8684 | Sell | $0.873 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 16.46 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -168.72 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -35.33 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | -0.17 | Sell |
| Ultimate (7,14,28) | 5.53 | Buy |
| Momentum (10) | -0.22 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.44 | Buy |
| ADX (14) | 32.00 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture for NRSN shows a NEUTRAL sentiment overall.
The RSI(14) is 20, and the 50-day simple moving average is $0.7332 while the 200-day simple moving average is $0.8757. Price support is identified at $0.48 and resistance at $0.805. The 30-day trading range spans from $0.3608 to $0.6391, highlighting recent volatility within a relatively tight band.
Annualized volatility is 80%, underscoring sizable swings relative to the price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.465 | $0.467 | $0.6647 | 0% | Neutral | |
| $0.3598 | $0.4726 | $0.6657 | +1% | Neutral | |
| $0.3437 | $0.4723 | $0.7013 | +1% | Neutral | |
| $0.4812 | $0.6865 | $1.06 | +47% | Bullish | |
| $0.5032 | $0.7425 | $1.19 | +59% | Bullish | |
| $0.4785 | $0.7283 | $1.20 | +56% | Bullish | |
| $0.4764 | $0.7465 | $1.26 | +60% | Bullish | |
| $0.4379 | $0.7054 | $1.22 | +51% | Bullish | |
| $0.4538 | $0.7508 | $1.33 | +61% | Bullish | |
| $0.5049 | $0.857 | $1.54 | +84% | Bullish | |
| $0.5369 | $1.03 | $2.01 | +120% | Bullish | |
| $1.17 | $2.60 | $5.71 | +457% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.465 | $0.467 | $0.5903 | +0.00% |
| September 2026 | $0.4275 | $0.5128 | $0.6375 | +9.81% |
| October 2026 | $0.4173 | $0.5059 | $0.6391 | -1.34% |
| November 2026 | $0.4064 | $0.4969 | $0.6357 | -1.78% |
| December 2026 | $0.4168 | $0.5137 | $0.6647 | +3.38% |
Click any year to see its month-by-month NRSN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NRSN could reach as high as $0.6647, with a base case around $0.467 and support toward $0.465 — roughly 0% from $0.467. Price action looks broadly range-bound.
Expect NRSN to range from $0.3598 to $0.6657 through 2027. The $0.4726 average target implies a +1% move from current prices. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
The NRSN price prediction for 2028 points to an average of $0.4723 (low $0.3437, high $0.7013) — a potential gain of +1% on today's $0.467. Price action looks broadly range-bound.
In 2029, NRSN is projected to trade between $0.4812 and $1.06, averaging $0.6865 — a potential gain of +47% from today's $0.467. That is up +45% on the projected 2028 average. Buyers look set to stay in control over this stretch.
NeuroSense Therapeutics Ltd.'s 2030 outlook centres on $0.7425, within a $0.5032 to $1.19 range. That is up +8% on the projected 2029 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2031, NRSN could reach as high as $1.20, with a base case around $0.7283 and support toward $0.4785 — roughly +56% from $0.467. Buyers look set to stay in control over this stretch.
Expect NRSN to range from $0.4764 to $1.26 through 2032. The $0.7465 average target implies a +60% move from current prices. That is up +3% on the projected 2031 average. Momentum favours further upside here.
The NRSN price prediction for 2033 points to an average of $0.7054 (low $0.4379, high $1.22) — a potential gain of +51% on today's $0.467. Buyers look set to stay in control over this stretch.
In 2034, NRSN is projected to trade between $0.4538 and $1.33, averaging $0.7508 — a potential gain of +61% from today's $0.467. That is up +6% on the projected 2033 average. Momentum favours further upside here.
NeuroSense Therapeutics Ltd.'s 2035 outlook centres on $0.857, within a $0.5049 to $1.54 range. That is up +14% on the projected 2034 average. That marks a +84% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NRSN could reach as high as $2.01, with a base case around $1.03 and support toward $0.5369 — roughly +120% from $0.467. Momentum favours further upside here.
Expect NRSN to range from $1.17 to $5.71 through 2050. The $2.60 average target implies a +457% move from current prices. That is up +153% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NRSN today (≈ 2,141.327623 NRSN) could be worth
$5,573.1
+$4,573.1 (+457%) by 2050 · US Dollar
Based on the average projected NRSN price of $2.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRSNwould be worth at today's price.
$1,000 invested in NRSN on Jul 31, 2025 (≈ 555.55557 NRSN) would be worth
$259.44
-$740.56 (-74.1%) today · 0.26× · US Dollar
Based on a NRSN entry price of $1.8 vs. today's $0.467.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.602 | $775.75 | -22.4% |
| 1 month ago | $0.723 | $645.92 | -35.4% |
| 3 months ago | $0.897 | $520.62 | -47.9% |
| 6 months ago | $0.93 | $502.15 | -49.8% |
| 1 year ago | $1.8 | $259.44 | -74.1% |
| All time (4.6y) ago | $4.04 | $115.59 | -88.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRSN forecast.
Our base-case forecast reaches $0.93 around 2040.
Implied market cap at $0.93: $33.57M
The multi-year forecast paints a clear upward trajectory beginning in the late 2020s and accelerating through the 2030s, 2040s, and into 2050. For 2029 the average price is $0.7085 with a max of $1.11 and a min of $0.4897, accompanied by a bullish sentiment and a 47.5 ROI. By 2030 the average rises to $0.7543 with a max of $1.23 and a min of $0.5029, delivering a 57.1 ROI and a bullish stance.
In 2031 the average is $0.7384 (max $1.24, min $0.4762) with a 53.8 ROI and a bullish sentiment, and by 2032 the average is $0.7638 (max $1.31, min $0.4774) with a 59.1 ROI and bullish sentiment. The path continues to 2033–2035 with still bullish sentiment and multi-year gains, reaching an average of $0.865 in 2035 (max $1.59, min $0.4958) and then accelerating further.
In 2040 the forecast shows a strong upshift to an average of $1.03 (max $2.05, min $0.5168) with an ROI of 114 and a bullish sentiment. By 2050 the average is projected at $2.62 (max $5.91, min $1.18) with an ROI of 446.6 and a bullish sentiment. These figures illustrate potential, not guarantees, and depend on clinical, regulatory, and market factors beyond the numbers alone.
Overall, the outlook suggests substantial upside over the long horizon, tempered by the uncertainties inherent in biotechnology equities and drug development timelines.
Tap a question to reveal the answer.
For 2030, the forecast shows an average price of $0.7543 with a min of $0.5029 and a max of $1.23, and an ROI of 57.1. The sentiment is BULLISH.
The forecast depicts a neutral stance in 2026–2028 and a bullish trend from 2029 onward, with the 2030–2050 period showing meaningful upside (e.g., 2030 avg $0.7543; 2040 avg $1.03; 2050 avg $2.62). Current price is $0.4802 and the 30-day range roughs out near $0.48–$0.64, but these are estimates and not guarantees.
The 2050 forecast shows an average of $2.62 with a max of $5.91 and a min of $1.18, which implies a potential to surpass $2 in the long term, depending on multiple factors. The 2050 ROI is 446.6 and sentiment is BULLISH.
The current price is $0.4802 and the market cap is $17.34M. The stock is ranked 4915.
The 30-day picture shows NEUTRAL sentiment with RSI(14) at 20, SMA50 at $0.7332, and SMA200 at $0.8757. Support is at $0.48 and resistance at $0.805, with a 30-day range from $0.3608 to $0.6391.
NeuroSense Therapeutics Ltd. Community Discussion
0Share your NeuroSense Therapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.